AR119902A1 - Proteínas de fusión terapéuticas - Google Patents
Proteínas de fusión terapéuticasInfo
- Publication number
- AR119902A1 AR119902A1 ARP200102479A ARP200102479A AR119902A1 AR 119902 A1 AR119902 A1 AR 119902A1 AR P200102479 A ARP200102479 A AR P200102479A AR P200102479 A ARP200102479 A AR P200102479A AR 119902 A1 AR119902 A1 AR 119902A1
- Authority
- AR
- Argentina
- Prior art keywords
- binding domain
- injury
- inflammatory
- fusion protein
- integrin
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 208000014674 injury Diseases 0.000 abstract 5
- 208000027418 Wounds and injury Diseases 0.000 abstract 4
- 230000006378 damage Effects 0.000 abstract 4
- 102000006495 integrins Human genes 0.000 abstract 4
- 108010044426 integrins Proteins 0.000 abstract 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 abstract 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 abstract 3
- 230000002757 inflammatory effect Effects 0.000 abstract 3
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 230000007928 solubilization Effects 0.000 abstract 2
- 238000005063 solubilization Methods 0.000 abstract 2
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 206010067125 Liver injury Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 231100000439 acute liver injury Toxicity 0.000 abstract 1
- 208000012998 acute renal failure Diseases 0.000 abstract 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 230000025194 apoptotic cell clearance Effects 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 239000013599 cloning vector Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 230000008736 traumatic injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/02—Services making use of location information
- H04W4/025—Services making use of location information using location based information parameters
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/02—Services making use of location information
- H04W4/029—Location-based management or tracking services
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Cell Biology (AREA)
- Signal Processing (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Telephone Function (AREA)
Abstract
Reivindicación 1: Una proteína de fusión terapéutica para potenciar la eferocitosis que comprende un dominio de unión a integrina, un dominio de unión a fosfatidilserina (PS) y un dominio de solubilización, donde el dominio de solubilización se inserta entre el dominio de unión a integrina y el dominio de unión a PS; y en donde el dominio de unión a integrina se une a una integrina. Reivindicación 15: Un ácido nucleico aislado que codifica la secuencia de aminoácidos de una cualquiera de las reivindicaciones 11 a 14. Reivindicación 16: Un vector de clonación o expresión que comprende el ácido nucleico de acuerdo con la reivindicación 15. Reivindicación 18: Una composición farmacéutica que comprende la proteína de fusión de una cualquiera de las reivindicaciones 1 a 14 y un portador farmacéuticamente aceptable. Reivindicación 19: La proteína de fusión de una cualquiera de las reivindicaciones 1 a 14 para su uso en el tratamiento o prevención de un trastorno inflamatorio o lesión orgánica inflamatoria en un individuo que lo necesite, en donde el trastorno inflamatorio o lesión orgánica inflamatoria es lesión renal aguda, síndrome de dificultad respiratoria aguda, lesión hepática aguda, sepsis, infarto de miocardio, accidente cerebrovascular, quemaduras, lesión traumática y lesiones inflamatorias y de órganos resultantes de isquemia / reperfusión.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19196045 | 2019-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119902A1 true AR119902A1 (es) | 2022-01-19 |
Family
ID=67875416
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102479A AR119902A1 (es) | 2019-09-06 | 2020-09-04 | Proteínas de fusión terapéuticas |
| ARP200102483A AR119905A1 (es) | 2019-09-06 | 2020-09-04 | Proteínas de fusión terapéuticas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102483A AR119905A1 (es) | 2019-09-06 | 2020-09-04 | Proteínas de fusión terapéuticas |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20230308835A1 (es) |
| EP (3) | EP4025238A1 (es) |
| JP (3) | JP2022547051A (es) |
| KR (3) | KR20220058588A (es) |
| CN (4) | CN114341194A (es) |
| AR (2) | AR119902A1 (es) |
| AU (3) | AU2020343512A1 (es) |
| BR (2) | BR112022003745A2 (es) |
| CA (3) | CA3152500A1 (es) |
| CO (2) | CO2022002567A2 (es) |
| CR (2) | CR20220096A (es) |
| CU (2) | CU20220016A7 (es) |
| EC (2) | ECSP22016180A (es) |
| IL (3) | IL290618A (es) |
| JO (2) | JOP20220055A1 (es) |
| MX (2) | MX2022002638A (es) |
| PE (2) | PE20221051A1 (es) |
| TW (2) | TW202122414A (es) |
| WO (3) | WO2021044360A1 (es) |
| ZA (2) | ZA202201828B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020084344A2 (en) * | 2018-10-25 | 2020-04-30 | Nexel Co., Ltd. | Compositions and methods for treating or preventing fibrosis |
| CN118076371A (zh) * | 2021-04-22 | 2024-05-24 | 百进生物科技公司 | 用于检测和耗竭磷脂酰丝氨酸阳性细胞的磷脂酰丝氨酸结合剂 |
| KR20230001168A (ko) | 2021-06-28 | 2023-01-04 | (주) 넥셀 | 특발성 폐섬유증 예방 또는 치료용 폴리펩타이드 및 이를 포함하는 약학 조성물 |
| CN114288386B (zh) * | 2022-01-25 | 2023-12-12 | 华中科技大学同济医学院附属协和医院 | Del-1作为炎症性肠病新的生物标志物及治疗药物应用 |
| TW202417520A (zh) * | 2022-10-14 | 2024-05-01 | 南韓商伊米斯療法股份有限公司 | 融合分子和治療免疫性疾病的方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
| EP1278544A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
| EP2277910A1 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CN101203234B (zh) | 2005-05-13 | 2012-10-10 | 范斯坦医药研究院 | 乳脂小球表皮生长因子-因子ⅷ和脓毒病 |
| CN101511866A (zh) * | 2006-09-08 | 2009-08-19 | Ambrx公司 | 经修饰的人类血浆多肽或Fc骨架和其用途 |
| WO2009064448A1 (en) | 2007-11-15 | 2009-05-22 | The Feinstein Institute For Medical Research | Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8 |
| EP2493921B1 (en) | 2009-10-30 | 2018-09-26 | Albumedix Ltd | Albumin variants |
| KR20130020765A (ko) | 2010-02-16 | 2013-02-28 | 메디뮨 엘엘씨 | Ｈｓａ-관련 조성물 및 사용방법 |
| KR20130070576A (ko) | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 유도체 및 변이체 |
| US20130225496A1 (en) | 2010-11-01 | 2013-08-29 | Novozymes Biopharma Dk A/S | Albumin Variants |
| WO2012112188A1 (en) | 2011-02-15 | 2012-08-23 | Medimmune, Llc | Hsa-related compositions and methods of use |
| US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
| CN103987401A (zh) * | 2011-04-28 | 2014-08-13 | 范斯坦医药研究院 | Mfg-e8及其用途 |
| MX353816B (es) | 2011-05-05 | 2018-01-30 | Albumedix As | Variantes de albumina. |
| US20140302027A1 (en) * | 2011-09-26 | 2014-10-09 | University Of Louisville Research Foundation, Inc. | Methods of treating periodontal inflammation and periodontal bone loss |
| GB2512156A (en) | 2012-11-08 | 2014-09-24 | Novozymes Biopharma Dk As | Albumin variants |
| EP2956002B1 (en) | 2013-02-16 | 2017-09-06 | Albumedix A/S | Pharmacokinetic animal model |
| US10030055B2 (en) | 2013-08-23 | 2018-07-24 | Riken | Polypeptide exhibiting fluorescent properties, and utilization of the same |
| WO2015150757A1 (en) * | 2014-03-31 | 2015-10-08 | British Telecommunications Public Limited Company | Data communication |
| EA201691795A1 (ru) * | 2014-03-31 | 2017-03-31 | Ханми Фарм. Ко., Лтд. | Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина |
| WO2015175512A1 (en) * | 2014-05-15 | 2015-11-19 | The Trustees Of The University Of Pennsylvania | Compositions and methods of regulating bone resorption |
| KR20170013621A (ko) | 2015-07-28 | 2017-02-07 | (주) 넥셀 | Ｍｉｌｋ ｆａｔ ｇｌｏｂｕｌｅ－ＥＧＦ ｆａｃｔｏｒ（ＭＦＧ－Ｅ８）을 이용한 조직섬유화 예방 또는 치료용 조성물 |
| CN118063619A (zh) * | 2017-03-02 | 2024-05-24 | 诺华股份有限公司 | 工程化的异源二聚体蛋白质 |
| US11028139B2 (en) | 2017-05-17 | 2021-06-08 | Nexel Co., Ltd. | Recombinant protein for preventing or treating tissue fibrosis and composition for preventing or treating tissue fibrosis comprising the same |
| WO2020084344A2 (en) | 2018-10-25 | 2020-04-30 | Nexel Co., Ltd. | Compositions and methods for treating or preventing fibrosis |
-
2020
- 2020-09-04 CU CU2022000016A patent/CU20220016A7/es unknown
- 2020-09-04 EP EP20768409.3A patent/EP4025238A1/en active Pending
- 2020-09-04 WO PCT/IB2020/058250 patent/WO2021044360A1/en active Application Filing
- 2020-09-04 KR KR1020227010907A patent/KR20220058588A/ko unknown
- 2020-09-04 WO PCT/IB2020/058252 patent/WO2021044362A1/en unknown
- 2020-09-04 AU AU2020343512A patent/AU2020343512A1/en active Pending
- 2020-09-04 TW TW109130528A patent/TW202122414A/zh unknown
- 2020-09-04 PE PE2022000372A patent/PE20221051A1/es unknown
- 2020-09-04 US US17/640,291 patent/US20230308835A1/en active Pending
- 2020-09-04 CA CA3152500A patent/CA3152500A1/en active Pending
- 2020-09-04 AU AU2020340618A patent/AU2020340618A1/en active Pending
- 2020-09-04 US US17/640,295 patent/US20230220048A1/en active Pending
- 2020-09-04 KR KR1020227010892A patent/KR20220058586A/ko unknown
- 2020-09-04 MX MX2022002638A patent/MX2022002638A/es unknown
- 2020-09-04 CR CR20220096A patent/CR20220096A/es unknown
- 2020-09-04 MX MX2022002637A patent/MX2022002637A/es unknown
- 2020-09-04 JP JP2022514570A patent/JP2022547051A/ja active Pending
- 2020-09-04 KR KR1020227010891A patent/KR20220058585A/ko unknown
- 2020-09-04 JP JP2022514843A patent/JP2022547111A/ja active Pending
- 2020-09-04 JO JOP/2022/0055A patent/JOP20220055A1/ar unknown
- 2020-09-04 BR BR112022003745A patent/BR112022003745A2/pt unknown
- 2020-09-04 EP EP20768410.1A patent/EP4025239A1/en active Pending
- 2020-09-04 AU AU2020343926A patent/AU2020343926A1/en active Pending
- 2020-09-04 US US17/640,293 patent/US20230265160A1/en active Pending
- 2020-09-04 JP JP2022514568A patent/JP2022547050A/ja active Pending
- 2020-09-04 CN CN202080061452.4A patent/CN114341194A/zh active Pending
- 2020-09-04 CN CN202410867790.7A patent/CN118667031A/zh active Pending
- 2020-09-04 JO JOP/2022/0058A patent/JOP20220058A1/ar unknown
- 2020-09-04 CA CA3152499A patent/CA3152499A1/en active Pending
- 2020-09-04 AR ARP200102479A patent/AR119902A1/es unknown
- 2020-09-04 BR BR112022003762A patent/BR112022003762A2/pt unknown
- 2020-09-04 CA CA3152990A patent/CA3152990A1/en active Pending
- 2020-09-04 WO PCT/IB2020/058251 patent/WO2021044361A1/en active Application Filing
- 2020-09-04 CN CN202080061624.8A patent/CN114341195A/zh active Pending
- 2020-09-04 CR CR20220089A patent/CR20220089A/es unknown
- 2020-09-04 EP EP20768408.5A patent/EP4025237A1/en active Pending
- 2020-09-04 CU CU2022000015A patent/CU20220015A7/es unknown
- 2020-09-04 CN CN202080061631.8A patent/CN114302896A/zh active Pending
- 2020-09-04 AR ARP200102483A patent/AR119905A1/es unknown
- 2020-09-04 PE PE2022000365A patent/PE20220401A1/es unknown
- 2020-09-07 TW TW109130667A patent/TW202122415A/zh unknown
-
2022
- 2022-02-11 ZA ZA2022/01828A patent/ZA202201828B/en unknown
- 2022-02-11 ZA ZA2022/01827A patent/ZA202201827B/en unknown
- 2022-02-14 IL IL290618A patent/IL290618A/en unknown
- 2022-02-16 IL IL290675A patent/IL290675A/en unknown
- 2022-02-16 IL IL290660A patent/IL290660A/en unknown
- 2022-03-03 EC ECSENADI202216180A patent/ECSP22016180A/es unknown
- 2022-03-03 CO CONC2022/0002567A patent/CO2022002567A2/es unknown
- 2022-03-03 CO CONC2022/0002545A patent/CO2022002545A2/es unknown
- 2022-03-04 EC ECSENADI202216558A patent/ECSP22016558A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119902A1 (es) | Proteínas de fusión terapéuticas | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| AR119080A1 (es) | Proteínas multiespecíficas | |
| PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
| AR076349A1 (es) | Peptido auxiliar del antigeno del cancer | |
| PE20181923A1 (es) | Neoantigenos y metodos de su uso | |
| CO6180445A2 (es) | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 | |
| PE20142114A1 (es) | Polipeptidos de receptores de activina variantes, solos o en combinacion con quimioterapia, y sus usos | |
| Dekan et al. | Total synthesis of human hepcidin through regioselective disulfide‐bond formation by using the safety‐catch cysteine protecting group 4, 4′‐dimethylsulfinylbenzhydryl | |
| CL2019003404A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico.(divisional solicitud 201702407) | |
| AR074399A1 (es) | Moleculas biespecificas de union a egfr/igfir | |
| AR091735A1 (es) | Complejo de factor viii con xten y proteina factor de von willebrand (vwf) y usos del mismo | |
| AR050353A1 (es) | Composicion de anticuerpo her2 | |
| AR038568A1 (es) | Anticuerpos anti-a beta y su uso | |
| NO20063026L (no) | Antistoffer | |
| AR071874A1 (es) | Proteinas de dominio de armazon basadas en fibronectina multivalentes | |
| AR080229A1 (es) | Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23) | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| AR059300A1 (es) | Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas | |
| AR113422A2 (es) | Agentes tensioactivos reconstituidos que tienen propiedades mejoradas | |
| AR056137A1 (es) | Un conjugado peptido inmunoglobulina y su uso como antiviral | |
| EA201790254A1 (ru) | Новые модуляторы рецептора glp-1 | |
| BR112018003594A2 (pt) | cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados | |
| CL2020003293A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 42; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) | |
| CY1110464T1 (el) | Παραγωγα πυραζολοπυριδινης ως αναστολεις του βητα-αδρενεργικου υποδοχεα της κινασης1 |